Drug Profile
Humanised anti-CD19 CAR-T cell therapy - Kite Pharma
Alternative Names: Third generation humanised anti-CD19 control CAR-T cell therapy - Kite PharmaLatest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator Kite Pharma
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological malignancies
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
- 03 Oct 2017 Kite Pharma has been acquired by Gilead Sciences
- 17 May 2017 Pharmacodynamics data from a preclinical trial in Haematological malignancies presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO - 2017)